{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:59:39Z","timestamp":1786982379951,"version":"build-2736575974"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2021,9,15]],"date-time":"2021-09-15T00:00:00Z","timestamp":1631664000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2021,9,15]],"date-time":"2021-09-15T00:00:00Z","timestamp":1631664000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Zambon"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1007\/s12325-021-01873-w","type":"journal-article","created":{"date-parts":[[2021,9,14]],"date-time":"2021-09-14T23:26:35Z","timestamp":1631661995000},"page":"5398-5411","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Effectiveness of Safinamide over Mood in Parkinson\u2019s Disease Patients: Secondary Analysis of the Open-label Study SAFINONMOTOR"],"prefix":"10.1007","volume":"38","author":[{"given":"Carmen M.","family":"Labandeira","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria G.","family":"Alonso Losada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosa","family":"Y\u00e1\u00f1ez Ba\u00f1a","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria I.","family":"Cimas Hernando","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iria","family":"Cabo L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose M.","family":"Paz Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria J.","family":"Gonzalez Palm\u00e1s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Mart\u00ednez Mir\u00f3","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3126-5111","authenticated-orcid":false,"given":"Diego","family":"Santos Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,9,15]]},"reference":[{"key":"1873_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2020.117109","volume":"418","author":"D Santos-Garc\u00eda","year":"2020","unstructured":"Santos-Garc\u00eda D, de Deus FT, Su\u00e1rez Castro E, et al. Quality of life and non-motor symptoms in Parkinson\u2019s disease patients with subthreshold depression. J Neurol Sci. 2020;418: 117109. https:\/\/doi.org\/10.1016\/j.jns.2020.117109.","journal-title":"J Neurol Sci"},{"key":"1873_CR2","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.jns.2019.05.009","volume":"402","author":"AJ Espay","year":"2019","unstructured":"Espay AJ, Foster ED, Coffey CS, et al. Lack of independent mood-enhancing effect for dopaminergic medications in early Parkinson\u2019s disease. J Neurol Sci. 2019;402:81\u20135. https:\/\/doi.org\/10.1016\/j.jns.2019.05.009.","journal-title":"J Neurol Sci"},{"key":"1873_CR3","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1007\/s40261-021-01011-y","volume":"41","author":"R Giossi","year":"2021","unstructured":"Giossi R, Carrara F, Mazzari M, et al. Overall efficacy and safety of safinamide in Parkinson\u2019s disease: a systematic review and a meta-analysis. Clin Drug Investig. 2021;41:321\u201339. https:\/\/doi.org\/10.1007\/s40261-021-01011-y.","journal-title":"Clin Drug Investig"},{"key":"1873_CR4","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1007\/s10072-018-3628-3","volume":"40","author":"LME Bianchi","year":"2019","unstructured":"Bianchi LME, Riboldazzi G, Mauri M, Versino M. Efficacy of safinamide on non-motor symptoms in a cohort of patients affected by idiopathic Parkinson\u2019s disease. Neurol Sci. 2019;40:275\u20139.","journal-title":"Neurol Sci"},{"key":"1873_CR5","doi-asserted-by":"publisher","first-page":"232","DOI":"10.3390\/brainsci11020232","volume":"11","author":"E Pe\u00f1a","year":"2021","unstructured":"Pe\u00f1a E, Borrue C, Mata M, et al. Impact of SAfinamide on Depressive Symptoms in Parkinson\u2019s Disease Patients (SADness-PD Study): a multicenter retrospective study. Brain Sci. 2021;11:232.","journal-title":"Brain Sci"},{"key":"1873_CR6","doi-asserted-by":"publisher","first-page":"629","DOI":"10.3233\/JPD-171143","volume":"7","author":"C Cattaneo","year":"2017","unstructured":"Cattaneo C, Muller T, Bonizzonic E, Lazzeria G, Kottakisa I, Keywoodd C. Long-term effects of safinamide on mood fluctuations in Parkinson\u2019s disease. J Parkinsons Dis. 2017;7:629\u201334.","journal-title":"J Parkinsons Dis"},{"key":"1873_CR7","doi-asserted-by":"publisher","first-page":"316","DOI":"10.3390\/brainsci11030316","volume":"11","author":"D Santos Garc\u00eda","year":"2021","unstructured":"Santos Garc\u00eda D, Labandeira Guerra C, Y\u00e1\u00f1ez Ba\u00f1a R, et al. Safinamide improves non-motor symptoms burden in Parkinson\u2019s disease: an open-label prospective study. Brain Sci. 2021;11:316.","journal-title":"Brain Sci"},{"key":"1873_CR8","first-page":"165","volume":"39","author":"S Daniel","year":"1993","unstructured":"Daniel S, Lees A. Parkinson\u2019s Disease Society Brain Bank, London: overview and research. J Neural Transm Suppl. 1993;39:165\u201372.","journal-title":"J Neural Transm Suppl"},{"key":"1873_CR9","doi-asserted-by":"publisher","first-page":"2314","DOI":"10.1002\/mds.21844","volume":"22","author":"B Dubois","year":"2007","unstructured":"Dubois B, Burn D, Goetz C, et al. Diagnostic procedures for Parkinson\u2019s disease dementia: recommendations from the Movement Disorder Society task force. Mov Disord. 2007;22:2314\u201324.","journal-title":"Mov Disord"},{"key":"1873_CR10","volume-title":"Diagnostic and statical manual of mental disorders","author":"American Psychiatric Association","year":"1994","unstructured":"American Psychiatric Association. Diagnostic and statical manual of mental disorders. 4th ed. Washington, DC: American Psychiatric Association; 1994.","edition":"4"},{"issue":"Suppl","key":"1873_CR11","first-page":"18","volume":"55","author":"LL Judd","year":"1994","unstructured":"Judd LL, Rapaport MH, Paulus MP, Brown JL. Subsyndromal symptomatic depression: a new mood disorder? J Clin Psychiatry. 1994;55(Suppl):18\u201328.","journal-title":"J Clin Psychiatry"},{"key":"1873_CR12","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1007\/s00415-011-6392-3","volume":"259","author":"P Martinez-Martin","year":"2012","unstructured":"Martinez-Martin P, Pecurariu CF, Odin P, et al. Gender-related differences in the burden of non-motor symptoms in Parkinson\u2019s disease. J Neurol. 2012;259:1639\u201347.","journal-title":"J Neurol"},{"key":"1873_CR13","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1002\/gps.5461","volume":"36","author":"D Santos-Garc\u00eda","year":"2021","unstructured":"Santos-Garc\u00eda D, De Deus FT, Cores BC, et al. Mood in Parkinson\u2019s disease: from early- to late-stage disease. Int J Geriatr Psychiatry. 2021;36:627\u201346.","journal-title":"Int J Geriatr Psychiatry"},{"key":"1873_CR14","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1002\/mds.25961","volume":"29","author":"R Borgohain","year":"2014","unstructured":"Borgohain R, Szasz J, Stanzione P, Meshram C, Bhatt MH. Two-year, randomized, controlled study of safinamide as add-on to levodopa in mid to late Parkinson\u2019s disease. Mov Disord. 2014;29:1273\u201380.","journal-title":"Mov Disord"},{"key":"1873_CR15","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1038\/225817a0","volume":"28","author":"GG Collins","year":"1970","unstructured":"Collins GG, Sandler M, Williams ED, Youdim MB. Multiple forms of human brain mitochondrial monoamine oxidase. Nature. 1970;28:817\u201320.","journal-title":"Nature"},{"key":"1873_CR16","doi-asserted-by":"publisher","first-page":"1719","DOI":"10.1007\/s00702-018-1942-9","volume":"125","author":"MBH Youdim","year":"2018","unstructured":"Youdim MBH. Monoamine oxidase inhibitors, and iron chelators in depressive illness and neurodegenerative diseases. J Neural Transm. 2018;125:1719\u201333. https:\/\/doi.org\/10.1007\/s00702-018-1942-9.","journal-title":"J Neural Transm"},{"key":"1873_CR17","doi-asserted-by":"publisher","first-page":"S287","DOI":"10.1038\/sj.bjp.0706464","volume":"147","author":"MBH Youdim","year":"2006","unstructured":"Youdim MBH, Bakhle YS. Monoamine oxidase: isoforms and inhibitors in Parkinson\u2019s disease and depressive illness. Br J Pharmacol. 2006;147:S287\u201396.","journal-title":"Br J Pharmacol"},{"key":"1873_CR18","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.phrs.2003.12.004","volume":"50","author":"A Marzo","year":"2004","unstructured":"Marzo A, Dal Bo L, Ceppi Monti N, et al. Pharmacokinetics and pharmacodynamics of safinamide, a neuroprotectant with antiparkinsonian and anticonvulsant activity. Pharmacol Res. 2004;50:77\u201385.","journal-title":"Pharmacol Res"},{"key":"1873_CR19","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1016\/S1474-4422(10)70106-X","volume":"9","author":"P Barone","year":"2010","unstructured":"Barone P, Poewe W, Albrecht S, et al. Pramipexole for the treatment of depressive symptoms in patients with Parkinson\u2019s disease: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2010;9:573\u201380.","journal-title":"Lancet Neurol"},{"key":"1873_CR20","doi-asserted-by":"publisher","first-page":"609","DOI":"10.2147\/DDDT.S77749","volume":"10","author":"F Stocchi","year":"2016","unstructured":"Stocchi F, Torti M. Adjuvant therapies for Parkinson\u2019s disease: critical evaluation of safinamide. Drug Des Devel Ther. 2016;10:609\u201318.","journal-title":"Drug Des Devel Ther"},{"key":"1873_CR21","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.1111\/ene.12724","volume":"22","author":"P Barone","year":"2015","unstructured":"Barone P, Santangelo G, Morgante L, et al. A randomized clinical trial to evaluate the effects of rasagiline on depressive symptoms in non-demented Parkinson\u2019s disease patients. Eur J Neurol. 2015;22:1184\u201391.","journal-title":"Eur J Neurol"},{"key":"1873_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.clineuro.2021.106523","volume":"202","author":"W Su","year":"2021","unstructured":"Su W, Liu H, Jiang Y, et al. Correlation between depression and quality of life in patients with Parkinson\u2019s disease. Clin Neurol Neurosurg. 2021;202: 106523. https:\/\/doi.org\/10.1016\/j.clineuro.2021.106523.","journal-title":"Clin Neurol Neurosurg"},{"key":"1873_CR23","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1002\/mds.21803","volume":"23","author":"JSAM Reijnders","year":"2008","unstructured":"Reijnders JSAM, Ehrt U, Weber WEJ, Aarsland D, Leentjens AFG. A systematic review of prevalence studies of depression in Parkinson\u2019s disease. Mov Disord. 2008;23:183\u20139.","journal-title":"Mov Disord"},{"key":"1873_CR24","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1002\/mdc3.13122","volume":"8","author":"C Rodriguez-Blazquez","year":"2020","unstructured":"Rodriguez-Blazquez C, Schrag A, Rizos A, Chaudhuri KR, Martinez-Martin P, Weintraub D. Prevalence of non-motor symptoms and non-motor fluctuations in Parkinson\u2019s disease using the MDS-NMS. Mov Disord Clin Pr. 2020;8:231\u20139.","journal-title":"Mov Disord Clin Pr"},{"key":"1873_CR25","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/j.jns.2011.07.007","volume":"310","author":"TC Van Der Hoek","year":"2011","unstructured":"Van Der Hoek TC, Bus BAA, Matui P, Van Der Marck MA, Esselink RA, Tendolkar I. Prevalence of depression in Parkinson\u2019s disease: effects of disease stage, motor subtype and gender. J Neurol Sci. 2011;310:220\u20134. https:\/\/doi.org\/10.1016\/j.jns.2011.07.007.","journal-title":"J Neurol Sci"},{"key":"1873_CR26","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/S1353-8020(03)00067-1","volume":"10","author":"A Rojo","year":"2003","unstructured":"Rojo A, Aguilar M, Garolera MT, Cubo E, Navas I, Quintana S. Depression in Parkinson\u2019s disease: clinical correlates and outcome. Parkinsonism Relat Disord. 2003;10:23\u20138.","journal-title":"Parkinsonism Relat Disord"},{"key":"1873_CR27","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1016\/j.parkreldis.2014.03.020","volume":"20","author":"A Sagna","year":"2014","unstructured":"Sagna A, Gallo J, Pontone GM, Sciences B, Hopkins J. Systematic review of factors associated with depression and anxiety disorders among older adults with Parkinson\u2019s disease. Parkinsonism Relat Disord. 2014;20:708\u201315.","journal-title":"Parkinsonism Relat Disord"},{"key":"1873_CR28","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1016\/j.parkreldis.2012.06.007","volume":"18","author":"AFG Leentjens","year":"2012","unstructured":"Leentjens AFG, Dujardin K, Marsh L, Martinez-martin P, Richard IH, Starkstein SE. Anxiety and motor fluctuations in Parkinson\u2019s disease: a cross-sectional observational study. Parkinsonism Relat Disord. 2012;18:1084\u20138. https:\/\/doi.org\/10.1016\/j.parkreldis.2012.06.007.","journal-title":"Parkinsonism Relat Disord"},{"key":"1873_CR29","doi-asserted-by":"publisher","DOI":"10.1155\/2021\/8871549","author":"D Santos Garc\u00eda","year":"2021","unstructured":"Santos Garc\u00eda D, De Deus FT, et al. Staging Parkinson\u2019s disease combining motor and non-motor symptoms correlates with disability and quality of life. Parkinsons Dis. 2021. https:\/\/doi.org\/10.1155\/2021\/8871549 (eCollection 2021).","journal-title":"Parkinsons Dis"},{"key":"1873_CR30","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/j.biopsych.2005.04.024","volume":"58","author":"GS Alexopoulos","year":"2005","unstructured":"Alexopoulos GS, Kiosses DN, Heo M, Murphy CF, Shanmugham B, Gunning-dixon F. Executive dysfunction and the course of geriatric depression. Biol Psychiatry. 2005;58:204\u201310.","journal-title":"Biol Psychiatry"},{"key":"1873_CR31","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1016\/j.parkreldis.2014.02.025","volume":"20","author":"AJH Moonen","year":"2014","unstructured":"Moonen AJH, Wijers A, Leentjens AFG, et al. Severity of depression and anxiety are predictors of response to antidepressant treatment in Parkinson\u2019s disease. Parkinsonism Relat Disord. 2014;20:644\u20136. https:\/\/doi.org\/10.1016\/j.parkreldis.2014.02.025.","journal-title":"Parkinsonism Relat Disord"},{"key":"1873_CR32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/2045125320985993","volume":"11","author":"YH Huang","year":"2021","unstructured":"Huang YH, Chen JH, Loh EW, Chan L, Hong CT. The effect of monoamine oxidase-B inhibitors on the alleviation of depressive symptoms in Parkinson\u2019s disease: meta-analysis of randomized controlled trials. Ther Adv Psychopharmacol. 2021;11:1\u20139.","journal-title":"Ther Adv Psychopharmacol"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-021-01873-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-021-01873-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-021-01873-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,28]],"date-time":"2021-09-28T05:10:08Z","timestamp":1632805808000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-021-01873-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,15]]},"references-count":32,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["1873"],"URL":"https:\/\/doi.org\/10.1007\/s12325-021-01873-w","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,15]]},"assertion":[{"value":"25 June 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 July 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 September 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}